CORVUS PHARMACEUTICALS INC (CRVS)
US2210151005 - Common Stock
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a...
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus...
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corvus Pharma (NASDAQ:CRVS) just reported results for the fourth quarter of 202...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications...
Corvus lymphoma drug gets FDA orphan drug status (NASDAQ:CRVS)
Corvus Pharmaceuticals (CRVS) receives FDA Orphan Drug Designation for soquelitinib, a potential treatment for T-cell lymphoma. Read more here.
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply...
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to...
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today...
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2-...
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition...
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumors Soquelitinib...